Mr. George Achilleos reports

NETRAMARK SIGNS CONTRACT WITH GLOBAL BIOPHARMACEUTICAL COMPANY TO ANALYZE PHASE 2 DEPRESSION TRIAL DATA

Netramark Holdings Inc. has signed a new contract with a leading global biopharmaceutical company developing innovative treatments for psychiatric and neurological disorders. The agreement will allow Netramark to analyze data from this client's phase 2 clinical trial for depression.

This collaboration supports NetraAI's continued use in the pharmaceutical industry as an artificial-intelligence-driven approach to understanding patient heterogeneity, dosing decisions and supporting study success rates.

"We believe this engagement reflects the demand from pharmaceutical companies to better understand the patient heterogeneity in clinical trials," said George Achilleos, chief executive officer of Netramark. "By analyzing this phase 2 data set, we aim to identify the patient subpopulations most likely to benefit from treatment and provide insights that may inform our sponsor's future study design with greater precision and confidence."

Under the agreement, Netramark will deploy its proprietary AI methodology to perform analyses on multidimensional clinical data to uncover potential patient phenotypes, evaluate treatment-related response patterns and generate hypothesis-driven insights.

This engagement further extends Netramark's growing portfolio of AI-driven projects in depression and CNS disorders as the company continues to demonstrate its capacity to deliver actionable precision trial insights that support drug development success for its clients.

Netramark's NetraAI platform leverages a dynamical systems framework which seeks to overcome the limitations of traditional machine learning, allowing it to work effectively with complex, small clinical data sets. The system is capable of stratifying high-effect-size patient subpopulations and translating insights into clinically meaningful criteria to enrich trials.

About Netramark Holdings Inc.

Netramark is a company focused on being a leader in the development of generative artificial intelligence/machine learning solutions targeted at the pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows Netramark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activate traditional AI/ML methods. The result is that Netramark can work with much smaller data sets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.

We seek Safe Harbor.